Carmell Co. (NASDAQ:CTCX) Sees Significant Growth in Short Interest

Carmell Co. (NASDAQ:CTCXGet Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 39,400 shares, an increase of 11.0% from the May 31st total of 35,500 shares. Based on an average daily trading volume, of 11,100 shares, the days-to-cover ratio is presently 3.5 days. Approximately 0.3% of the company’s stock are short sold.

Carmell Stock Performance

CTCX stock traded up $0.31 during trading on Monday, hitting $1.64. 33,076 shares of the company’s stock traded hands, compared to its average volume of 9,080. The business has a fifty day simple moving average of $2.10 and a two-hundred day simple moving average of $2.79. Carmell has a 1 year low of $1.11 and a 1 year high of $13.31.

Carmell (NASDAQ:CTCXGet Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Carmell

An institutional investor recently bought a new position in Carmell stock. Hubbell Strickland Wealth Management LLC purchased a new position in Carmell Co. (NASDAQ:CTCXFree Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 12,548 shares of the company’s stock, valued at approximately $32,000. Hubbell Strickland Wealth Management LLC owned about 0.07% of Carmell at the end of the most recent quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Carmell Company Profile

(Get Free Report)

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.

See Also

Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.